ACS names three new members to board

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Cancer Society announced the election of three new members of its board of directors:

Amit Kumar, of San Jose, CA, executive chairman of ITUS Corporation, a cancer diagnostic company;

Joseph Naylor of San Ramon, CA, vice president of policy, government, and public affairs for Chevron Corp., a position he has held since April 2016.

William Novelli of Bethesda, MD, professor in the McDonough School of Business at Georgetown University and former CEO of AARP.

In other developments:

Arnold Baskies, of Cherry Hill, NJ, became chair of the board. Baskies is a medical director at Virtua Health Systems in southern New Jersey, where he specializes in surgical oncology and general surgery.

Kevin Cullen, of Baltimore, became vice chair. Cullen is the director at the University of Maryland Marlene and Stewart Greenebaum Cancer Center

Lewis Foxhall, of Houston, became board scientific officer. Foxhall is the vice president for health policy and professor of clinical cancer prevention at MD Anderson Cancer Center;

John Alfonso, of Bellerose Village, NY, became sctretary/treadurer. Alfonso is a partner in the CohnReznick LLP New York office and leads the efforts of the firm’s not-for-profit and education industry practice in New York; and

Scarlott Mueller, of Gainesville, FL, became immediate past chair. Mueller is a former vice president and chief nursing officer at the North Florida
Regional Medical Center.

The ACS board consists of 21 members, including five officers and 16 directors. Directors are elected for a two-year term, and officers hold their position for a one-year term. The Board is responsible for setting policy, establishing long-term goals, monitoring general operations, and approving the organizational outcomes and allocation of resources.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login